- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00766753
Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas
A Phase I/II Evaluation of Vaccination With Type 1 Dendritic Cells Pulsed With Multiple Peptides in the Treatment of HLA-A2 Positive Patients With Recurrent Malignant Gliomas
Study Overview
Status
Conditions
Detailed Description
This is a single-institution Phase I/II study designed to evaluate the safety, the induction of an immune response, and the preliminary clinical response of vaccinations with Type-1 αDCs (αDC1) loaded with glioma-associated antigen (GAA) epitopes and administration of poly-ICLC in patients with recurrent malignant gliomas. The hypothesis is that this form of vaccines in combination with poly-ICLC treatment will prove to be safe, and will induce potent anti-glioma immune responses.
The primary objective is to establish the safety of the approach.
The secondary objectives are to 1) assess the immunological response against GAAs in patients with recurrent malignant gliomas immunized with DCs loaded with GAA-derived peptides using enzyme-linked immuno-spot (ELISPOT), delayed-type hypersensitivity (DTH) and tetramer assays and 2) assess the preliminary anti-tumor clinical activity of the vaccines as measured by radiological response (MRI), overall survival, and four- and six-month progression-free survival (PFS).
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- Hillman Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must have a histologically confirmed
- recurrent glioblastoma (GBM)
- anaplastic astrocytoma (AA)
- anaplastic oligodendroglioma (AO)
- anaplastic mixed oligoastrocytoma (AMO)
- other anaplastic glioma
- Patients must have received prior external beam radiotherapy and/or chemotherapy unless patients refused the options.
- Patients may have had treatment for no more than 2 prior relapses. Relapse is defined as progression following initial therapy (i.e. radiation +/- chemo if that was used as initial therapy).
- Patients must be HLA-A2 positive.
- All patients must sign an informed consent document indicating that they are aware of the investigational nature of this study.
- Patients must sign an authorization for the release of their protected health information.
- Patients must be > 18 years old, and with a life expectancy > 8 weeks. -Patients must have a Karnofsky performance status of > 60.
- Patients must have recovered from the toxic effects of prior therapy: 4 weeks from any investigational agent, 4 weeks from prior cytotoxic therapy and/or at least two weeks from vincristine, 4 weeks from nitrosoureas, 3 weeks from procarbazine administration, and 1 week for non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count). Any questions related to the definition of non-cytotoxic agents should be directed to the principal investigator.
- Patients must not have any disease that will obscure toxicity or dangerously alter drug metabolism.
- Patients must not have any serious concurrent medical illness.
- Documented negative serum beta-HCG for female patients of child-bearing age.
- Patients must be free of systemic infection. Subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection. Subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment.
Patients must have adequate organ function as measured by:
Hematopoietic:
- granulocytes at least 2500/mm3
- lymphocytes at least 1000/mm3
- platelets at least 100,000/mm3
- hemoglobin at least 10.0 g/dL
- Cardiac: Asymptomatic or, if symptomatic, then left ventricular ejection fraction at rest must be at least 50% or within the normal range of the institution. A cardiology clearance will be required for LV ejection fraction 50%.
- Hepatic: AST, ALT, GGT, LDH, Alk phos within 2.5 x upper normal limit and total bilirubin no greater than 2.0 mg/dL.
- Renal: Serum creatinine up to 1.5 x upper normal limit.
- Pretreatment baseline evaluations for laboratory parameters must be obtained within 10 to 18 days of subject registration.
Exclusion Criteria:
- Pregnant or breast-feeding.
- Presence of metastatic disease.
- Active bacterial, viral or fungal infections. Subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection. Subjects on antibiotic therapy must be off antibiotics for at least 7 days before beginning treatment.
- Chemotherapy, biologic therapy or radiation therapy less than one month prior to study entry.
- History or presence of autoimmune disease.
- Use of immunosuppressives within 4 weeks prior to study entry or anticipated use of immunosuppressive agents. Minimum doses of corticosteroid (dexamethasone up to 4 mg/day) is permitted.
- Subjects with uncontrolled pain. -Subjects who have sensitivity to drugs to provide local anesthesia.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single
All consenting, eligible subjects receive the intervention
|
Subjects will receive four (4) injections of the vaccine into the lymph nodes.
Injection is guided by ultrasonography.
Subjects will receive the first cycle of vaccine in the right groin.
Two weeks after the first vaccine, subjects receive the same vaccine at the left groin, followed by the 3rd and the 4th vaccines in the left and right armpits, respectively, with two-week intervals.
Each injection contains 0.2cc (less than 1/20th of a teaspoon) of a saline solution containing the vaccine cell mixture.
This phase will begin at week 13.
These subjects will be treated with additional vaccinations every 4 weeks to a maximum of 5 vaccine injections and, if poly-ICLC is available from the supplier starting on the day of the first additional vaccine and twice/week for 8 injections following each additional vaccine.
If poly-ICLC supply is not available from the supplier, DC vaccines only will be given in the booster phases.
At week 33, following the completion of 5 additional vaccines, if participants demonstrate stable disease or positive clinical response, if poly-ICLC supply is still available, participants will be offered additional DC-vaccines and poly-ICLC treatment. The second phase booster vaccines can be continued as long as the patient shows continued positive response or stable disease (both radiological and clinically) with no major adverse events, and as long as funding is available for the study. DC vaccines in this phase will be administered every 6 months+/- 2 weeks. 2). Poly-ICLC at 10µg/kg and up to 1640 µg/injection will be administered intramuscularly (i.m.) on the day of each booster DC vaccine. Poly-ICLC will be administered weekly thereafter for twice (at one week and two weeks after each vaccine) (e.g. if the previous DC vaccine was administered on a Thursday, subsequent poly-ICLC will be administered on the next two Thursdays |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Experienced Treatment-related Dose Limiting Toxicities (DLT)
Time Frame: up to 8 weeks
|
Number of participants who experienced treatment-related Dose Limiting Toxicities (DLT) at any dose level.
|
up to 8 weeks
|
Median Time To Progression
Time Frame: At baseline, 9, 17, 25, and 33 weeks, and every 3 months; up to 23 months
|
Median number of months until disease progression.
Tumor size was assessed using magnetic resonance imaging (MRI) scans with contrast enhancement to detect change from baseline.
|
At baseline, 9, 17, 25, and 33 weeks, and every 3 months; up to 23 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
12-month- Progression Free Survival (PFS)
Time Frame: Up to 12 months
|
Number of patients with progression-free status lasting at least 12 months
|
Up to 12 months
|
Overall Survival (OS)
Time Frame: Up to 102 months
|
Time interval from start of treatment until date of death.
|
Up to 102 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Frank Lieberman, MD, University of Pittsburgh
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 05-115
- NIH/NINDS/NCI
- 1R21CA117152-01A2 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Glioma
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III GliomaUnited States
-
Henry FriedmanCompletedGrade IV Malignant GliomaUnited States
-
Annick DesjardinsAmgenTerminated
-
Kentuckiana Cancer InstituteEisai Inc.UnknownNewly Diagnosed Supratentorial Malignant GliomaUnited States
-
AmgenCompletedGlioblastoma or Malignant GliomaUnited States, Australia, Netherlands, Germany, Spain, France
-
Duke UniversityMonteris MedicalWithdrawnGlioblastoma | Malignant Glioma of BrainUnited States
-
CellabMEDRecruitingRecurrent Malignant GliomaKorea, Republic of
-
University of ChicagoRecruitingMalignant Glioma of BrainUnited States
-
Angiochem IncCompletedRecurrent or Progressive Malignant GliomaUnited States
Clinical Trials on Dendritic vaccine pulsed with multiple peptides
-
The Republican Research and Practical Center for...Belarusian State Medical UniversityCompletedPancreatic Neoplasms | Dendritic CellsBelarus
-
Hospital Clinic of BarcelonaCompleted
-
University of Sao Paulo General HospitalNot yet recruiting
-
Sara VareaCompletedMultiple Sclerosis | Neuromyelitis OpticaSpain
-
Beijing Tiantan HospitalZhongSheng BioTech Inc.Active, not recruitingGlioblastoma Multiforme of BrainChina
-
Leo W. Jenkins Cancer CenterH. Lee Moffitt Cancer Center and Research InstituteTerminatedMetastatic Pancreatic CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteActive, not recruiting
-
Duke UniversityNational Cancer Institute (NCI)Completed
-
H. Lee Moffitt Cancer Center and Research InstituteAbramson Cancer Center at Penn MedicineCompletedBreast CancerUnited States
-
Abramson Cancer Center of the University of PennsylvaniaCompleted